
The Danish-based biotech group Genmab has signed a commercial agreement concerning its DuoBody technology with Germany’s Biontech in the immuno-oncology field, Genmab writes in an announcement.
The deal will see the two companies jointly research, develop and commercialize bispecific antibody products using Genmab’s DuoBody technology platform.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app